Back to Search Start Over

Adult Xp11.2 translocation renal cell carcinoma managed effectively with pazopanib

Authors :
Cristian Solano
Mohammad Muhsin Chisti
Shrinjaya B. Thapa
Source :
BMJ Case Rep
Publication Year :
2021
Publisher :
BMJ, 2021.

Abstract

Xp11.2 translocation renal cell carcinoma (TRCC) is a rare and aggressive variant of renal cell carcinoma (RCC) when presenting in adults. We report a case of a man in his early 40s who was diagnosed with stage III Xp11.2 TRCC and underwent radical nephrectomy. Seven months following the surgery, an adrenal nodule and bilateral pulmonary nodules were discovered. He underwent cryoablation of the adrenal nodule and systemic treatment with daily pazopanib. He displayed stable disease for approximately 6 years. Following this period, multiple hospitalisations interrupted daily pazopanib therapy resulting in progression of disease. His regimen was then changed to ipilimumab and nivolumab, followed by current daily therapy with axitinib. The patient now shows stable disease in his 10th year after diagnosis. This case study demonstrates the efficacy of pazopanib for metastatic Xp11.2 TRCC and warrants further investigation to supplement the guidelines regarding the use of targeted therapy for TRCC.

Details

ISSN :
1757790X
Volume :
14
Database :
OpenAIRE
Journal :
BMJ Case Reports
Accession number :
edsair.doi.dedup.....5c8b847bb4fc733aa2317365c7ebf22e
Full Text :
https://doi.org/10.1136/bcr-2021-243058